MBS Item 14245 – Changes to administration eligibility for immunomodulating agents

This page provides information on amendments to Medicare Benefits Schedule (MBS) item 14245 commencing on 1 November 2026, relating to the administration of immunomodulating agent services billed under the MBS.

Page last updated: 30 October 2026

From 1 November 2026, MBS item 14245 will allow immunomodulating agents to be administered by a broader range of qualified health professionals on behalf of a medical practitioner, aligning with current clinical practice. Patient eligibility and access remain unchanged.

Further information is available in the below factsheet:

Word Version - Factsheet for 1 November 2026 immunomodulating agent MBS item 14245 changes.docxWord Version - Factsheet for 1 November 2026 immunomodulating agent MBS item 14245 changes.docx

PDF Version - Factsheet for 1 November 2026 immunomodulating agent MBS item 14245 changes.pdfPDF Version - Factsheet for 1 November 2026 immunomodulating agent MBS item 14245 changes.pdf

In this section